Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report - PubMed
3 hours ago
- #real-world outcomes
- #third-line therapy
- #multiple myeloma
- The study evaluated therapy choices and outcomes for relapsed multiple myeloma patients starting third-line therapy using a Canadian database of over 10,000 patients with plasma cell disorders.
- Among 1,125 patients, the most common third-line therapies were immunomodulatory agents (62.4%), proteasome inhibitors (43.6%), and anti-CD38 monoclonal antibodies (24.6%).
- Combinations of daratumumab plus lenalidomide, with or without corticosteroids, produced the best responses with a median progression-free survival of 25.6 months.
- Other regimens, including anti-CD38 monoclonal antibodies with pomalidomide or other proteasome inhibitor-based therapies, had significantly shorter median progression-free survival, ranging from 6 to 9 months.
- Adverse prognostic factors included high-risk fluorescence in situ hybridization, shorter time from diagnosis to third-line therapy, triple-class exposure, previous proteasome inhibitor exposure, and refractoriness to lenalidomide.
- The median overall survival for patients undergoing third-line therapy was 29.7 months, highlighting the efficacy of anti-CD38 monoclonal antibodies combined with lenalidomide in improving third-line outcomes.
- This Canadian report provides benchmark outcomes and information on resource use that will aid stakeholders in the evolving therapeutic landscape for multiple myeloma.